Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Merck
AstraZeneca
Baxter
Johnson and Johnson

Last Updated: September 25, 2022

SUPPRELIN LA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Supprelin La patents expire, and when can generic versions of Supprelin La launch?

Supprelin La is a drug marketed by Endo Pharm and is included in one NDA. There is one patent protecting this drug.

This drug has three patent family members in three countries.

The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.

DrugPatentWatch® Generic Entry Outlook for Supprelin La

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 16, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for SUPPRELIN LA
Drug Prices for SUPPRELIN LA

See drug prices for SUPPRELIN LA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for SUPPRELIN LA
Generic Entry Date for SUPPRELIN LA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
IMPLANT;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SUPPRELIN LA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
Southwest Oncology GroupPhase 3
University of Colorado, DenverPhase 2

See all SUPPRELIN LA clinical trials

US Patents and Regulatory Information for SUPPRELIN LA

SUPPRELIN LA is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SUPPRELIN LA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SUPPRELIN LA

Compositions and methods for treating precocious puberty
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SUPPRELIN LA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 See Plans and Pricing See Plans and Pricing
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SUPPRELIN LA

When does loss-of-exclusivity occur for SUPPRELIN LA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Patent: 70960
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 73293
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SUPPRELIN LA around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2006009801 See Plans and Pricing
European Patent Office 0551698 Fabrication d'articles hydrophiles hydro-gonflables et dispositifs de délivrance de médicaments (Manufacture of water - swellable hydrophilic articles and drug delivery devices) See Plans and Pricing
Canada 2059377 FABRICATION D'ARTICLES HYDROPHILES GONFLANT DANS L'EAU ET DISPOSITIFS D'ADMINISTRATION DE MEDICAMENTS (MANUFACTURE OF WATER-SWELLABLE HYDROPHILIC ARTICLES AND DRUGDELIVERY DEVICES) See Plans and Pricing
Australia 1018392 See Plans and Pricing
Canada 2059377 FABRICATION D'ARTICLES HYDROPHILES GONFLANT DANS L'EAU ET DISPOSITIFS D'ADMINISTRATION DE MEDICAMENTS (MANUFACTURE OF WATER-SWELLABLE HYDROPHILIC ARTICLES AND DRUGDELIVERY DEVICES) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
AstraZeneca
Express Scripts
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.